| Patient | Satchel Paige |
|---|---|
| Date of birth | 1906-07-07 |
| Identifiers | MRN HR-ML047-SYN-TD; SSN (made up) 000-47-3381 |
| Document date | 1979-09-08 |
| Author | Delphine Whitaker-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Eight-week review: the new inhaler, rehabilitation, the screening CT and lipids. [S]
Mr. Paige returns six weeks after starting umeclidinium-vilanterol and eight weeks after starting atorvastatin. He takes the inhaler every morning and has not missed a dose; he has no dry mouth or trouble passing urine. He can now walk to the store without stopping, and uses albuterol two or three times a week. He has been to eight rehabilitation sessions and walks on the days between. He has had no flare-up. His low-dose CT five weeks ago showed emphysema in the upper lobes, a 4 mm nodule with a benign appearance, and calcium in the coronary arteries; he has no chest pain on exertion. He has had no muscle aches on atorvastatin. [S]
| Element | Detail |
|---|---|
| Symptoms | CAT 14, from 18; mMRC 1 |
| Reliever use | Two or three times a week |
| Low-dose CT | Centrilobular emphysema; 4 mm nodule, Lung-RADS 2; moderate coronary calcification |
| Lipids | LDL 86 mg/dL, from 148 |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Less breathless; little morning sputum; no wheeze |
| Cardiovascular | Negative | No chest pain, pressure or palpitations on exertion; no ankle swelling |
| Genitourinary | Negative | No hesitancy or poor stream |
| Musculoskeletal | Negative | No muscle aches |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Albuterol 90 micrograms per inhalation metered-dose inhaler with a spacer, two inhalations every four hours as needed for breathlessness | Two inhalations with a spacer every 4 hours as needed | Respiratory tract route | 1979-07-14 | active | S |
| Umeclidinium 62.5 micrograms with vilanterol 25 micrograms dry powder inhaler (a LAMA with a LABA), one inhalation once a day | One inhalation each morning; a strong, deep breath in | Respiratory tract route | 1979-07-28 | active | S |
| Atorvastatin 20 mg tablet once a day | One tablet each evening | Oral route | 1979-07-14 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1979-09-08 | Body height | 191 | cm | S |
| 1979-09-08 | Body weight | 82.8 | kg | S |
| 1979-09-08 | Body mass index (BMI) [Ratio] | 22.7 | kg/m2 | S |
| 1979-09-08 | Systolic blood pressure | 130 | mm[Hg] | S |
| 1979-09-08 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1979-09-08 | Heart rate | 78 | /min | S |
| 1979-09-08 | Respiratory rate | 16 | /min | S |
| 1979-09-08 | Body temperature | 36.6 | Cel | S |
| 1979-09-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1979-09-08 | Cholesterol [Mass/volume] in Serum or Plasma | 158 | mg/dL | <=199 mg/dL | Normal | S |
| 1979-09-08 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46 | mg/dL | >=40 mg/dL | Normal | S |
| 1979-09-08 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 86 | mg/dL | <=99 mg/dL | Normal | S |
| 1979-09-08 | Triglyceride [Mass/volume] in Serum or Plasma | 130 | mg/dL | <=149 mg/dL | Normal | S |
Vital signs recorded on 1979-09-08; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Comfortable; blood pressure 130/78, pulse 78, oxygen saturation 95 percent on room air |
| Respiratory | Reduced breath sounds; no wheeze or crackles |
| Cardiovascular | Regular rhythm; no edema |
| Inhaler technique | Dry powder inhaler used correctly with a strong, deep breath in and a breath-hold |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness on exertion for about two years, now after one flight of stairs or a block on the level (mMRC 2), with a morning cough and a little clear sputum most days; no chest pain, ankle swelling, orthopnea, wheeze at rest or weight loss; a former smoker of about 30 pack-years; cause under evaluation with spirometry and a pulmonology consultation | resolved | confirmed | R06.09 | S — Synthetic presenting problem anchored to his documented emphysema; superseded when spirometry at the consultation confirmed COPD. |
| Chronic obstructive pulmonary disease, GOLD grade 2 (post-bronchodilator FEV1/FVC 0.58, FEV1 61% predicted by the race-neutral GLI Global equations), GOLD group B (CAT 18, mMRC 2, no exacerbation in the past year); alpha-1 antitrypsin normal; blood eosinophils 0.08 x 10^3/uL; synthetic modern diagnosis linked to his documented emphysema | active | confirmed | J44.9 | S — Synthetic modern diagnosis made at the consultation, anchored to his documented emphysema; its onset and course in the modern episode are synthetic. |
| Former cigarette smoker, about 30 pack-years, stopped eleven years ago on his own; no use since | active | confirmed | Z87.891 | S — Synthetic smoking history: whether he smoked is not documented in the sources read, so the history is synthetic and labeled as such. |
| Hyperlipidemia: LDL 148 mg/dL, HDL 44 and triglycerides 160 at intake; estimated 10-year cardiovascular risk about 18 percent; atorvastatin started by shared decision | active | confirmed | E78.5 | S — Synthetic cardiovascular risk factor anchored to his documented heart trouble; not a claim about his real lipids. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Symptoms: CAT and mMRC dyspnea scale | Every visit | Completed today | CAT 14; mMRC 1 |
| Survey | Exacerbations in the past 12 months (moderate and severe) and GOLD group | Every visit | Completed today | None; group B |
| Examination | Pulse oximetry at rest | Every visit | Completed today | 95 percent on room air |
| Laboratory | Spirometry: post-bronchodilator FEV1/FVC and FEV1 % predicted (race-neutral GLI Global) | At diagnosis, then at least yearly or with a clear change | Up to date | Diagnostic spirometry six weeks ago; repeat in a year |
| Self-management | Smoking status and cessation support | Every visit | Completed today | Smoke-free |
| Examination | BMI and nutrition | Every visit | Completed today | BMI 22.7 |
| Medication safety | Inhaler technique, adherence and side effects (dry mouth, urinary retention) | Every visit | Completed today | Correct technique; no missed doses; no dry mouth or urinary symptoms |
| Imaging | Low-dose CT lung cancer screening | Yearly at 50 to 80 with 20 or more pack-years, while within fifteen years of quitting | Completed today | Done five weeks ago: Lung-RADS 2 (4 mm solid nodule); emphysema; coronary calcification; next in twelve months |
| Referral | Pulmonary rehabilitation | Offer when mMRC is 2 or more, or CAT 10 or more; within three weeks of a hospital discharge for an exacerbation | Completed today | Eight of twenty sessions completed |
| Laboratory | Lipid panel after starting a statin | Four to twelve weeks after starting, then yearly | Completed today | Total cholesterol 158, HDL 46, LDL 86, triglycerides 130 mg/dL |
| Medication safety | Statin safety: muscle symptoms | Every visit | Completed today | No muscle aches |
| Examination | ECG and cardiovascular risk | At baseline; reassess after exacerbations | Up to date | Normal ECG at intake; coronary calcification noted on CT; no angina |
| Self-management | Vaccines: influenza, pneumococcal, RSV, COVID-19, Tdap, zoster | Yearly review | Due | Influenza, RSV, COVID-19 and zoster at the wellness visit in four weeks |
| Examination | Long-term oxygen assessment | When resting PaO2 is 55 mm Hg or less (60 with cor pulmonale or polycythemia) or saturation 88 percent or less, confirmed twice | Not indicated | Saturation 95 percent; no change since the blood gas |
Goal progress:
Guideline basis: Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement (2023); CMID: Clinical Monitoring Intelligence Database, COPD and hyperlipidemia monographs (2026); Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023); Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020); A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation (LOTT) (2016); Racial Bias in Pulse Oximetry Measurement (2020); Lung Cancer: Screening (2021); Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022); Adult Immunization Schedule by Age (2026)
Follow-up: Wellness visit with vaccines in four weeks. Fifteen-week review in seven weeks. Next scheduled visit 1979-10-06: subsequent annual wellness visit. [S]